2024
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221
Chen C, Zirpoli G, Budd G, Barlow W, Pusztai L, Hortobagyi G, Albain K, Godwin A, Thompson A, Henry N, Ambrosone C, Stringer K, Hertz D. Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221. Cancer Chemotherapy And Pharmacology 2024, 94: 311-321. PMID: 38814343, PMCID: PMC11878155, DOI: 10.1007/s00280-024-04680-6.Peer-Reviewed Original ResearchCIPN severityPeripheral neuropathyPaclitaxel-induced peripheral neuropathyEarly-stage breast cancerTrial of patientsBackgroundChemotherapy-induced peripheral neuropathyBody mass indexSerum amino acid concentrationsOver-representation analysisDebilitating neurotoxicityPaclitaxel scheduleAnti-cancer agentsBreast cancerSelf-reported raceMass indexMetabolic pathways of amino acidsSerum concentrationsInverse associationAmino acid metabolic pathwaysPaclitaxelPrimary analysisBonferroni correctionTreatment limitationsS0221CIPN
2023
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research
Wientjes M, Lu Z, Chan C, Turaga K, Au J. Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research. Journal Of Controlled Release 2023, 361: 717-726. PMID: 37574051, PMCID: PMC10560040, DOI: 10.1016/j.jconrel.2023.08.017.Peer-Reviewed Original ResearchConceptsCytoreductive surgeryIntraperitoneal chemotherapyPatient ascitesPeritoneal metastasisPM patientsTreatment of peritoneal metastasesPresence of ascitesAccumulation of ascitesProtein bindingTumor locationTumor sizeSystemic treatmentAscites samplesAscitesClinical advancesAAG concentrationPatient managementTreatment outcomesPaclitaxelVariable efficacyPatientsProteomic analysisFree fractionAscites proteinsHyperthermic temperaturesConcurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence functionPaclitaxel effects on axonal localization and vesicular trafficking of NaV1.8
Baker C, Tyagi S, Higerd-Rusli G, Liu S, Zhao P, Dib-Hajj F, Waxman S, Dib-Hajj S. Paclitaxel effects on axonal localization and vesicular trafficking of NaV1.8. Frontiers In Molecular Neuroscience 2023, 16: 1130123. PMID: 36860665, PMCID: PMC9970094, DOI: 10.3389/fnmol.2023.1130123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyDorsal root gangliaPTX treatmentDRG axonsEffect of paclitaxelVoltage-gated sodium channel NaPain syndromePeripheral neuropathyDRG neuronsSodium channel NaRoot gangliaCell cycle arrestNeuronal somataSensory neuronsSide effectsTherapeutic targetingTumor growthPaclitaxel effectAntineoplastic agentsAxonal localizationPaclitaxelNumber of NaAxonal compartmentAxonsChannel NaTargeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xie X, Yang Y, Wang Q, Liu H, Fang X, Li C, Jiang Y, Wang S, Zhao H, Miao J, Ding S, Liu X, Yao X, Yang W, Jiang J, Shao Z, Jin G, Bian X. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research 2023, 33: 215-228. PMID: 36627348, PMCID: PMC9977947, DOI: 10.1038/s41422-022-00766-z.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-L1Combination therapyTherapeutic responsePD-1/PD-L1 signalingShorter progression-free survivalBreast cancer benefitProgression-free survivalPD-L1 signalingCheckpoint inhibitorsNab-paclitaxelCancer benefitImmunotherapy cohortImmune microenvironmentPreclinical resultsTumor cell membranesTumor samplesPaclitaxelHigh expressionPromising targetPatientsTherapyTumorsResistant factorATAD3A expression
2022
Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer
Gao D, Asghar S, Ye J, Zhang M, Hu R, Wang Y, Huang L, Yuan C, Chen Z, Xiao Y. Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer. Carbohydrate Polymers 2022, 294: 119785. PMID: 35868795, DOI: 10.1016/j.carbpol.2022.119785.Peer-Reviewed Original ResearchConceptsBreast cancerHyaluronic acid nanogelsTumor-bearing BALB/c miceTherapy of breast cancerTreatment of breast cancerTargeting breast cancerBreast cancer cellsRat pharmacokinetic profilesIn vivo studiesTherapeutic efficacyBALB/c miceEntrapment efficiencyPharmacokinetic profileCancer cellsClearance rateCD44 receptorControl groupCancerPaclitaxelDrug loadingHigher cytotoxicityReceptorsCD44DrugCells
2021
SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Chung H, Lee K, Kim W, Gainor J, Lakhani N, Chow L, Messersmith W, Fanning P, Squifflet P, Jin F, Forgie A, Wan H, Pons J, Randolph S, LoRusso P. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals Of Oncology 2021, 32: s215-s216. DOI: 10.1016/j.annonc.2021.05.055.Peer-Reviewed Original ResearchAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal Of Clinical Oncology 2021, 39: 2375-2385. PMID: 34077270, DOI: 10.1200/jco.20.03398.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalT-DM1Breast cancerStage IStage I HER2-positive breast cancerHER2-positive breast cancerHuman epidermal growth factor receptorAdjuvant T-DM1Co-primary objectivesDisease-free survivalPatient-reported outcomesEpidermal growth factor receptorGrowth factor receptorProtocol therapyAnalysis populationTrastuzumab emtansineClinical trialsRelevant toxicityPatientsFactor receptorLess toxicityWeeksTrastuzumabCancerPaclitaxelMachine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
Sundar R, Kumarakulasinghe N, Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan A, Hoppe M, Jeyasekharan A, Ng C, De Simone M, Grabsch H, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021, 71: 676-685. PMID: 33980610, PMCID: PMC8921574, DOI: 10.1136/gutjnl-2021-324060.Peer-Reviewed Original ResearchConceptsDisease free survivalValidation cohortGastric cancerGene signatureSurvival benefitPac-SensitiveNo survival differenceSelection of patientsGC trialsFree survivalPaclitaxel chemotherapyCurative surgeryMetastatic patientsPredictive biomarkersTraining cohortSurvival differencesIndependent cohortNanoString panelGC patientsPaclitaxelPatientsNanoString profilingCohortGroup trialUFTThe impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.Peer-Reviewed Original ResearchFTD/TPI treatmentSafety profileAdverse eventsSafety of FTD/TPIGastroesophageal junction cancerThird-line chemotherapySecond-line treatmentPost hoc analysisHematologic toxicityOS benefitChemotherapy regimensJunction cancerSurvival benefitEfficacy benefitsFTD/TPIRamucirumabTagging trialsPlaceboPaclitaxelPrior treatmentAssociated with benefitsHoc analysisInfluence outcomesChemotherapySubgroup A
2018
An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients
Moore LM, Wilkinson R, Altan M, Toki M, Carvajal-Hausdorf DE, McGuire J, Ehrlich BE, Rimm DL. An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. Npj Breast Cancer 2018, 4: 6. PMID: 29560416, PMCID: PMC5847580, DOI: 10.1038/s41523-018-0057-7.Peer-Reviewed Original ResearchTaxane-based neoadjuvant chemotherapyPathological complete responseNeuronal calcium sensor-1Neoadjuvant chemotherapyNCS-1 expressionBreast cancer patientsPoor clinical outcomeEfficacy of paclitaxelBreast cancer biopsiesComplete responseClinical outcomesCancer patientsPredictive biomarkersBreast cancerCancer biopsiesChemotherapyElevated expressionPaclitaxelPrevious studiesResponseBiopsyPatientsExpressionTaxanesCancerOATP1B2 deficiency protects against paclitaxel-induced neurotoxicity
Leblanc A, Sprowl J, Alberti P, Chiorazzi A, Arnold W, Gibson A, Hong K, Pioso M, Chen M, Huang K, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen R, Reinbolt R, Lustberg M, Sucheston-Campbell L, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal Of Clinical Investigation 2018, 128: 816-825. PMID: 29337310, PMCID: PMC5785270, DOI: 10.1172/jci96160.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkersCell Line, TumorGenotypeHEK293 CellsHumansHyperalgesiaInhibitory Concentration 50Liver-Specific Organic Anion Transporter 1MCF-7 CellsMiceMice, Inbred DBAMice, KnockoutMice, TransgenicOrganic Anion TransportersPaclitaxelPeripheral Nervous System DiseasesPhenotypePyrimidinesConceptsPaclitaxel-induced neurotoxicityDose-limiting peripheral neurotoxicityTyrosine kinase inhibitor nilotinibAction potential amplitudeKinase inhibitor nilotinibPeripheral neurotoxicityThermal hyperalgesiaTherapeutic managementPotential amplitudeNeurotoxicityAnticancer propertiesNoncompetitive mechanismAnticancer drugsPaclitaxelAllodyniaHyperalgesiaPotential implicationsNilotinibOatp1b2Mice
2017
Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study
Sundar R, Bandla A, Tan S, Liao L, Kumarakulasinghe N, Jeyasekharan A, Ow S, Ho J, Tan D, Lim J, Vijayan J, Therimadasamy A, Hairom Z, Ang E, Ang S, Thakor N, Lee S, Wilder-Smith E. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Frontiers In Oncology 2017, 6: 274. PMID: 28119855, PMCID: PMC5222823, DOI: 10.3389/fonc.2016.00274.Peer-Reviewed Original ResearchNerve conduction studiesBreast cancer patientsPeripheral neuropathyPaclitaxel infusionLimb hypothermiaPreventing paclitaxel-induced peripheral neuropathyCancer patientsPaclitaxel-induced peripheral neuropathyHistory of diabetes mellitusDose-limiting toxicityCompound muscle action potentialCool limbsMuscle action potentialWeekly paclitaxelSensory velocityDiabetes mellitusGrade 2Contralateral limbAction potentialsPaclitaxelPilot trialPatientsControl limbsHypothermiaTolerance to hypothermia
2016
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy
Sundar R, Jeyasekharan A, Pang B, Soong R, Kumarakulasinghe N, Ow S, Ho J, Lim J, Tan D, Wilder-Smith E, Bandla A, Tan S, Asuncion B, Fazreen Z, Hoppe M, Putti T, Poh L, Goh B, Lee S. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy. PLOS ONE 2016, 11: e0164319. PMID: 27716814, PMCID: PMC5055363, DOI: 10.1371/journal.pone.0164319.Peer-Reviewed Original ResearchConceptsPaclitaxel-induced neuropathySevere neuropathyReceiver operating characteristicNerve tissueDose-limiting toxicityEarly breast cancerSensory peripheral neuropathyArea under the curveBreast cancer patientsIntensity of stainingWeekly paclitaxelSurgical resectionCharcot-Marie-ToothLimiting toxicitiesPredictive biomarkersNerve biopsyPeripheral neuropathyBreast cancerBiomarker strategiesCancer patientsNDRG1 expressionNeuropathyExpression scorePatientsPaclitaxelOutcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Semrad T, Redman M, Herbst R, Kim E, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Hirsch F, Kelly K, Gandara D. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 9082-9082. DOI: 10.1200/jco.2016.34.15_suppl.9082.Peer-Reviewed Original ResearchPhase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.Peer-Reviewed Original Research
2014
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy.
Denlinger C, Sym S, Bendell J, Alsina M, Watkins D, Chao Y, Cubillo A, Kunz P, Sun W, Baeksgaard L, Chen L, Horgan K, Frye S, Kudla A, McDonagh C, Czibere A, Moyo V, Chibaudel B, Bang Y. Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. Journal Of Clinical Oncology 2014, 32: tps4148-tps4148. DOI: 10.1200/jco.2014.32.15_suppl.tps4148.Peer-Reviewed Original ResearchE2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer.
Cohen S, Feng Y, Catalano P, Mitchell E, O'Dwyer P, Lubner S, Fisher G, Mulcahy M, Burtness B, Benson A. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. Journal Of Clinical Oncology 2014, 32: 4020-4020. DOI: 10.1200/jco.2014.32.15_suppl.4020.Peer-Reviewed Original ResearchGene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
Carey L, Barry W, Pitcher B, Hoadley K, Cheang M, Anders C, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Perou C, Winer E, Hudis C. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal Of Clinical Oncology 2014, 32: 506-506. DOI: 10.1200/jco.2014.32.15_suppl.506.Peer-Reviewed Original ResearchEarly phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG).
Tawbi H, Chu E, Lin Y, Hyman D, Goel S, Rudek M, Dowlati A, LoRusso P, Mulkerin D, Chew H, Kiesel B, Pollice L, Appleman L, Puhalla S, Stoller R, Lee J, Ivy P, Beumer J. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). Journal Of Clinical Oncology 2014, 32: 2572-2572. DOI: 10.1200/jco.2014.32.15_suppl.2572.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply